Cost-effectiveness analysis of voriconazole versus amphotericin B in the treatment of invasive aspergillosis in Spain

被引：2

作者：

Grau, S

Mateu-de, AJ

Soto, J

Muñoz, M

Salas, E

机构：

[1] Univ Autonoma Barcelona, Hosp Mar, Dept Med, E-08003 Barcelona, Spain

[2] Pfizer SA, Madrid, Spain

来源：

VALUE IN HEALTH | 2003年 / 6卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)61912-2

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：750 / 751

页数：2

共 50 条

[1] Cost-effectiveness of voriconazole versus amphotericin B deoxicolate for the primary treatment of invasive aspergillosis
Aiello, EC
Devoto, FM
Dignani, C
De Vedia, L
Lorenzo, H
VALUE IN HEALTH, 2006, 9 (03) : A155 - A155
[2] COST-EFFECTIVENESS ANALYSIS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXYCHOLATE IN THE TREATMENT OF INVASIVE PULMONARY ASPERGILLOSIS IN COLOMBIA
Lemos, E., V
Cortes, J.
Gutierrez-Ardila, M., V
Nunez, S. M.
Prieto, H. A.
VALUE IN HEALTH, 2012, 15 (04) : A243 - A243
[3] Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis
Greene, Reginald E.
Mauskopf, Josephine
Roberts, Craig S.
Zyczynski, Teresa
Schlamm, Haran T.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (24) : 2561 - 2568
[4] Cost-effectiveness of voriconazole versus liposomal amphotericin B for invasive aspergillosis infection in the UK
Mesrobian, X
Loftus, J
Roberts, C
Jansen, J
VALUE IN HEALTH, 2005, 8 (06) : A20 - A20
[5] COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS
Verheggen, B. G.
Heeg, B. M. S.
Vos, C. B. J.
Van Hout, B. A.
VALUE IN HEALTH, 2008, 11 (06) : A437 - A437
[6] COST-EFFECTIVENESS ANALYSIS OF ISAVUCONAZOLE VERSUS VORICONAZOLE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN JORDAN
Naser, A.
Bilbisi, M.
Mousa, R.
VALUE IN HEALTH, 2023, 26 (12) : S116 - S116
[7] Cost-effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium
Marbaix, S
Marciniak, A
De Mees, V
Aoun, M
VALUE IN HEALTH, 2003, 6 (06) : 750 - 750
[8] Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
Lefteris Floros
Daniel Kuessner
Jan Posthumus
Emma Bagshaw
Jan Sjölin
BMC Infectious Diseases, 19
[9] Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
Floros, Lefteris
Kuessner, Daniel
Posthumus, Jan
Bagshaw, Emma
Sjolin, Jan
BMC INFECTIOUS DISEASES, 2019, 19 (1)
[10] Cost-minimization analysis of voriconazole and liposomal Amphotericin B for the treatment of invasive candida and aspergillosis infections in Spain
Aguado, JM
Díaz, C
González, P
Fernández, I
Viudes, A
VALUE IN HEALTH, 2005, 8 (06) : A63 - A64

← 1 2 3 4 5 →